Lead Product(s): Egrifta
Therapeutic Area: Infections and Infectious Diseases Product Name: F8
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
This new formulation, known as “F8”, is stable at room temperature for up to seven days after reconstitution and its volume of administration is only 0.16 mL making it possible to have a single multidose vial containing seven days of treatment.